Introduction: Individuals in the Alzheimer's disease (AD) continuum with mild cognitive impairment (prodromal AD) are at increased risk to develop dementia. Still, underlying pathophysiological processes remain unclear. We studied whether cerebrospinal fluid (CSF) proteome changes are related to time to clinical progression in prodromal AD. Methods: We measured 671 CSF proteins in 49 prodromal AD individuals (67±7 years old, 22 [45%] female) from the Amsterdam Dementia Cohort. Associations of protein levels with time to dementia onset were tested with Cox regression models, followed by biological pathway enrichment analysis. Results: Eighteen (36%) individuals developed dementia during follow-up. In total, 128 (98%) proteins were associated...
Objective: To use proteomic analysis of cerebrospinal fluid to discover novel proteins and peptides ...
Clinicopathological studies suggest that Alzheimer's disease (AD) pathology begins ∼10–15 years befo...
Alzheimer’s disease (AD) pathology develops many years before the onset of cognitive symptoms. Two p...
Introduction: Individuals in the Alzheimer's disease (AD) continuum with mild cognitive impairment (...
Although neuropsychiatric symptoms (NPS) are common and severely affect older people with cognitive ...
Alzheimer’s disease (AD) is the most common cause of dementia and is characterized by aggregation of...
Development of disease-modifying therapies against Alzheimer’s disease (AD) requires biomarkers refl...
Providing an accurate prognosis for individual dementia patients remains a challenge since they grea...
The fact that cerebrospinal fluid (CSF) deeply irrigates the brain together with the relative simpli...
Abstract Neurodegenerative diseases are a growing burden, and there is an urgent need for better bio...
A crucial need exists for reliable Alzheimer's disease (AD) diagnostic and prognostic tests. Given i...
Abstract Background Altered proteome profiles have been reported in both postmortem brain tissues an...
Background: We investigated whether a panel of 12 potential novel biomarkers consisting of proteins ...
In this exploratory neuroimaging-proteomic study, we aimed to identify CSF proteins associated with ...
<div><p>In this exploratory neuroimaging-proteomic study, we aimed to identify CSF proteins associat...
Objective: To use proteomic analysis of cerebrospinal fluid to discover novel proteins and peptides ...
Clinicopathological studies suggest that Alzheimer's disease (AD) pathology begins ∼10–15 years befo...
Alzheimer’s disease (AD) pathology develops many years before the onset of cognitive symptoms. Two p...
Introduction: Individuals in the Alzheimer's disease (AD) continuum with mild cognitive impairment (...
Although neuropsychiatric symptoms (NPS) are common and severely affect older people with cognitive ...
Alzheimer’s disease (AD) is the most common cause of dementia and is characterized by aggregation of...
Development of disease-modifying therapies against Alzheimer’s disease (AD) requires biomarkers refl...
Providing an accurate prognosis for individual dementia patients remains a challenge since they grea...
The fact that cerebrospinal fluid (CSF) deeply irrigates the brain together with the relative simpli...
Abstract Neurodegenerative diseases are a growing burden, and there is an urgent need for better bio...
A crucial need exists for reliable Alzheimer's disease (AD) diagnostic and prognostic tests. Given i...
Abstract Background Altered proteome profiles have been reported in both postmortem brain tissues an...
Background: We investigated whether a panel of 12 potential novel biomarkers consisting of proteins ...
In this exploratory neuroimaging-proteomic study, we aimed to identify CSF proteins associated with ...
<div><p>In this exploratory neuroimaging-proteomic study, we aimed to identify CSF proteins associat...
Objective: To use proteomic analysis of cerebrospinal fluid to discover novel proteins and peptides ...
Clinicopathological studies suggest that Alzheimer's disease (AD) pathology begins ∼10–15 years befo...
Alzheimer’s disease (AD) pathology develops many years before the onset of cognitive symptoms. Two p...